|Bid||98.00 x 100|
|Ask||161.78 x 100|
|Day's Range||150.61 - 153.96|
|52 Week Range||128.58 - 163.75|
|PE Ratio (TTM)||18.93|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Morgan Stanley named three reasons for its positive opinion on Irish pharma company Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) in a Monday report. The Analyst Analyst David Risinger upgraded shares of Jazz ...
Jazz Pharmaceuticals (JAZZ) earnings and revenues miss estimates in Q4. However, the company posts a strong bottom and top-line guidance for 2018.
The Dublin-based company said it had profit of $3.79 per share. Earnings, adjusted for one-time gains and costs, were $2.95 per share. The results fell short of Wall Street expectations. The average estimate ...
On Tuesday, Jazz Pharmaceuticals (NASDAQ: JAZZ ) will release its latest earnings report. Here is Benzinga's outlook for the company. Earnings and Revenue Wall Street expects EPS of $3.00 and sales around ...
The number of biotech stocks posting gains outstripped those recording losses for the week. Notable among the gainers for the week were Odonate Therapeutics Inc (NASDAQ: ODT ) — which reported its financial ...
In Q4, we expect investors' focus on Xyrem's performance, Jazz Pharmaceuticals' (JAZZ) lead product for excessive daytime sleepiness. Also, hopes will be pinned on the company's pipeline progress.
Examining Jazz Pharmaceuticals Public Limited Company’s (NASDAQ:JAZZ) past track record of performance is an insightful exercise for investors. It allows us to reflect on whether or not the company hasRead More...
Valeant Pharmaceuticals (VRX) is a specialty pharmaceutical company involved in the development, manufacture, and marketing of branded, generic, branded generic as well as over the counter products. Of the seven analysts covering Valeant Pharmaceuticals in February 2018, two analysts have given the stock a “buy” or higher rating. Three analysts have given it a “hold” rating, and two analysts have given the stock a “sell” rating.
Shares of Concert Pharmaceuticals (CNCE) nosedive after the Patent Trial and Appeal Board decided not to grant a Post Grant Review petition in patent '335 dispute with Incyte.
In 3Q17, Jazz Pharmaceuticals’ (JAZZ) Erwinaze generated revenue of $49 million, which reflected a rise of ~14% on a year-over-year (or YoY) basis.
In 3Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenue of $303.9 million, which reflected a rise of ~6% on a YoY (year-over-year) basis.